论文部分内容阅读
目的分析异位妊娠患者应用米非司酮联合甲氨蝶呤治疗的临床路径及预期效果。方法选取该院妇科2013年1月—2015年5月收治的72例异位妊娠患者作为研究对象,采用随机数字分组法将72例患者均分为观察组与对照组。对照组36例患者单纯给予甲氨蝶呤药物治疗方案,观察组36例患者于对照组治疗基础之上联用米非司酮药物治疗,对比二组患者临床疗效及预后情况差异。结果经临床不同药物方案保守治疗后,二组患者妊娠包块及血β-hCG水平等指标,相比治疗前均得到了显著改善,但观察组患者各项指标改善程度显著优于同期对照组患者(P<0.05);且二组患者临床疗效对比可知,观察组患者临床治愈率达91.66%,对照组患者临床治愈率为77.78%,组间疗效差异显著,P<0.05,具有统计学意义。结论针对异位妊娠患者,给予患者米非司酮联合甲氨蝶呤药物治疗方案,具有着确切的临床疗效及治疗安全性,可进一步强化患者预后,值得临床综合应用推广。
Objective To analyze the clinical application of mifepristone combined with methotrexate in patients with ectopic pregnancy and its expected outcome. Methods Seventy-two patients with ectopic pregnancy admitted to our hospital from January 2013 to May 2015 were enrolled in this study. All the 72 patients were divided into observation group and control group by random number grouping method. Thirty-six patients in the control group were treated with methotrexate alone. 36 patients in the observation group were treated with mifepristone on the basis of the control group, and the clinical efficacy and prognosis of the two groups were compared. Results After conservative treatment with different clinical drug regimens, the indexes of pregnancy mass and blood β-hCG in the two groups were significantly improved compared with those before treatment, but the improvement of each index in the observation group was significantly better than that in the control group (P <0.05). The comparison of clinical curative effect between the two groups shows that the clinical cure rate in the observation group reaches 91.66% and the clinical curative rate in the control group is 77.78%, the difference between the two groups is significant (P <0.05) . Conclusion For patients with ectopic pregnancy, given mifepristone combined with methotrexate drug treatment program, with the exact clinical efficacy and safety of treatment, can further enhance the prognosis of patients, it is worth the promotion of comprehensive clinical application.